Voglibose: An alpha glucosidase inhibitor

Journal of Clinical and Diagnostic Research

Volumn 7, Issue 12, 2013, Pages 3023-3027

  Dabhi, Ajay S ^a   Bhatt, Nikita R ^a   Shah, Mohit J ^a  

^a Govt Medical College   (India)

Author keywords

Alpha glucosidase inhibitors ( GI); Postprandial hyperglycaemia (PPHG)

Indexed keywords

ACARBOSE; ALOGLIPTIN; ALPHA AMYLASE PANCREAS ISOENZYME; APOLIPOPROTEIN A; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FIBRIC ACID DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIVER ENZYME; MELANIN; METFORMIN; MIGLITOL; MITIGLINIDE; MONOAMINE OXIDASE A INHIBITOR; SALICYLIC ACID; SULFONYLUREA; VOGLIBOSE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ARTICLE; BLOATING; CHOLESTASIS; CLINICAL TRIAL (TOPIC); DIARRHEA; DIZZINESS; DRUG OVERDOSE; EPIGASTRIC FULLNESS; FLATULENCE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCOGEN STORAGE DISEASE; HEPATITIS; HUMAN; IMMUNOTHERAPY; KIDNEY DYSFUNCTION; LACTATION; LIVER DISEASE; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PEDIATRICS; PREGNANCY;

EID: 84890466586     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2013/6373.3838     Document Type: Article

References (30)

1. Ceriello A. The emerging role of post perdanial hyperglycaemic spikes in pathogenesis of diabetes complications. Diabetec Med. 1998;15: 188-93.
2. The Diabetes Control And Complications Trial Research Group (DCCT): the relationship of glycemic exposure (HBA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995; 44-968-83.
3. Yamasaki, et al. Alpha glucosidase inhibitor reduce the progression of carotid intima thickness. Diabetes Res Clin Pract. 2005; 67 (3): 204-10.
4. Standards of medical care in diabetes-2012. Diabetes Care. 2012; 35(Suppl. 1): S11-S63.
5. Goke B, et al. voglibose is an efficient glucosidase inhibitor and mobilises the endogenous GLP ! reserve. Digestion. 1995;56 (6): 493-501.
6. Takahisa H, et al., Characteristics of hyper diabetic patients responds to voglibose administration as an adjunct to sulfonylurea. Diabetes Research and Clinical Practice. 2000;54: 9-15.
7. http://www.idf.org/treatment-algorithm-people-type-2-diabetes: 2013.
8. Ikeda Y, Tajima D, Yokoyama J, et al. effect of AO-123 (voglibose) on blood glycose reduction in IDDM. Shinyaku to Rinsho. 1992; 41: 20-28.
9. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K.[Alpha-glucosidase inhibitor for the prevention of Type 2 diabetes mellitus: a randomised, double-blind trial in Japanese subjects with impaired glucose tolerance]. Nippon Rinsho. Japanese Journal of Clinical Medicine. 2009;67(9): 1821-25.
10. Bin BH, Seo J, Yang SH, Lee E, Choi H, Kim KH, Cho EG, Lee TR. Novel inhibitory effect of the anti-diabetic drug voglibose on melanogenesis. Experimental Dermatology. 2013; 22(8):541-46.
11. Ihara K, et al. Prevention of hypoglycaemia in a patient with type I b glucogon storage disease be an amylase inhibitor. Acta Paediatric. 1998; 87: 545-98.
12. Koh N, Sakamoto S, Chino F. Improvement in medication compliance and glycemic control with voglibose oral disintegrating tablet. Tohoku J Exp Med. 2008;216(3):249-57.
13. Ruder H, et al. The alpha glycosidase inhibitor voglibose (AO-128) does not change pharmacodynamics or pharmacokinetics of warfarin. J Clin-Pharmacology 1997; 5b; 153-57.
14. Kojima K, Tsujimoto T, Fujii H, Morimoto T, Yoshioka S, Kato S, et al. Pneumatosis cystoides intestinalis induced by the α-glucosidase inhibitor miglitol. Intern Med. 2010;49:1545-48.
15. Saito N, et al. Effect of an alphglucosidase inhibitor in combination with sulfonylurea. J of International Medical Research. 1998;26: 219-32.
16. Matsumoto K, et al, combination therapy of alpha glucosidase inhibitor and a sulfonylurea compound prolongs the duration of good glycemic control. Metabolism 2002; 51 (12): 1548-52.
17. Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K. Alogliptin plus voglibose in Japanese patients with Type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Curr Med Res Opin. 2011; 27suppl 3:21-29.
18. Hiyoshi T, Shiozaki M, Inoue M, Takahashi T, Nishikawa F, Naito H, et al. Clinical study of a fixed-dosed mitiglinide/voglibose combination in patients with Type 2 diabetes mellitus-Clinical assessment of glycemic markers, HbA1c, glycated albumin and 1,5-anhydroglucitol. Therapeutic Research. 2013; 34(3):379-90.
19. Takami K, et al. effects of Dietary Treatment alone or diet with voglibose or Glyboride on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed Type 2 Diabetes. Diabetes Care 2002;25:658-62.
20. Fujitaka K, Otani H, Jo F, Jo H, Nomura E, Iwasaki M, et al. Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome. Endocrine Journal. 2011;58(6): 425-32.
21. Negishi M, Shimomura K, Proks P, Shimomura Y, Mori M. Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients. Br J Clin Pharmacol. 2008;66(2):318-19.
22. Abe M, Kikuchi F, Kaizu K, Matsumoto K. Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese Type 2-diabetic patients on hemodialysis. Clin Nephrol. 2007;68:287-94.
23. Kawagishi T, et al., Improvement in insulin sensitivity and dyslipidemia with alpha glycosidase inhibitor voglibose in non diabetic hyperinsulinemic subjects. Diabetes Care 1997 Oct; 20(10) 1529-320.
24. Vichayanrat A, et al-Alpha glucosidase inhibitor reduces the progression of carotid intima-media thickness. Diabetes Res Clin Pract. 2002 Feb; 55 (2): 99-103.
25. Kataoka Y, Yasuda S, Miyamoto Y, Sase K, Kosuge M, Kimura K, et al. Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients. Circulation Journal. 2012;76(3): 712-20.
26. Fujisawa T, et al. Effect two alpha glusidase inhibitors. Voglibose and acarbose on post predanial hyperglycaemic concelates with subjective abdominal symptoms. Metabolism. 2005; 54 (3): 387-90.
27. Vichayanrat A, Ploybutr S, Tunlakit M, Watanakejorn P. Efficacy and safety of voglibose in comparison with acarbose in Type 2 diabetic patients. Diabetes Res. Clin. Pract. 2002;55:99-103.
28. Arshang D, et al. Drug therapy of post prandial hypreglycemia. Drugs. 1999; 57 (1): 19-29.
29. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of Type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet, 2002;359 (9323): 2072-2077.
30. Chiasson JL, Josse RG, Gomis R, Hanefeld, M, Karasik A, Laakso M. Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients with Impaired Glucose Tolerance: The STOP-NIDDM Trial. Journal of the American Medical Association. 2003;290 4: 486-94.